GFAP and amyloidosis: Importantly, these decreases in gliosis were accompanied by a parallel reduction in amyloid plaque deposition, indicating that KBN2202 mitigates both neuroinflammation and amyloid pathology within affected hippocampal regions (GFAP + Thio S: Veh, 24.5 ± 1.2 plaques/mm2; 5 mg/kg, 10.1 ± 1.3 plaques/mm2; 20 mg/kg, 15.0 ± 3.4 plaques/mm2, Figure 6c) (Iba1 + Thio S: Veh, 19.3 ± 3.1 plaques/mm2; 5 mg/kg, 7.4 ± 1.7 plaques/mm2; 20 mg/kg, 7.6 ± 0.6 plaques/mm2, Figure 6f).